Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2138525 | 0.99 | HTR7 (0.50) | HTR7POLBPKMSMN1; SMN2ABCB1 | |
| SCHEMBL10035598 | 0.88 | POLB (0.62) | HTR7POLBABCB1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2138910 | 0.87 | POLB (0.61) | HTR7POLBABCB1TMEM97SIGMAR1 | |
| SCHEMBL2139964 | 0.85 | HTR7 (0.69) | HTR7POLBPKM | |
| SCHEMBL8982167 | 0.85 | HTR7 (0.59) | HTR7POLBABCB1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5402009 | 0.85 | HTR7 (0.68) | HTR7POLBPKM | |
| Hydrochloric Acid SCHEMBL4230226 | 0.84 | HTR7 (0.58) | HTR7POLBABCB1TMEM97SIGMAR1 | |
| SCHEMBL10035645 | 0.84 | HTR7 (0.55) | HTR7POLBABCB1TMEM97SIGMAR1 | |
| SCHEMBL10035595 | 0.83 | ABCB1 (0.64) | HTR7PKMABCB1 | |
| SCHEMBL10035624 | 0.83 | MBTD1 (0.59) | HTR7ABCB1NPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885POLB 3250/4885PKM 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.